{
    "clinical_study": {
        "@rank": "142916", 
        "acronym": "MACBETH", 
        "arm_group": {
            "arm_group_label": "0.5mg AFLIBERCEPT injection", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12,  patients will receive an additional injection."
        }, 
        "brief_summary": {
            "textblock": "Patients with neovascular age-related macular degeneration who do not respond to usual\n      treatment with conventional medications may respond to a new drug of the same class which is\n      designed to block a larger fraction of proangiogenic factors."
        }, 
        "brief_title": "Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Wet Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Wet Macular Degeneration"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed Informed Consent\n\n          -  Men and women \u2265 50 years of age.\n\n          -  Any choroidal neovascular membranes (CNVM) lesion (occult, minimally classic or\n             classic) secondary to age-related macular degeneration\n\n          -  Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity of:\n             20/32 to 20/320 (letter score of 73 to 25) in the study eye.\n\n          -  Able to return for ALL clinic visits and complete all study-related procedures.\n\n          -  Absence of other ocular diseases that could affect visual acuity.\n\n          -  Patients without optimal response to ranibizumab or bevacizumab defined as:\n\n               -  Patient with significant persistent or recurrent fluid (intraretinal or\n                  subretinal) on OCT or any leakage on fluorescein angiography despite at least 4\n                  injections within last 6 months, being the last OCT with presence of fluid\n                  within the 6 weeks after last treatment with ranibizumab or bevacizumab.\n\n               -  Patient with significant persistent or recurrent fluid (intraretinal or\n                  subretinal) on OCT or any leakage on fluorescein angiography despite three\n                  monthly treatment with ranibizumab or bevacizumab.\n\n        Exclusion Criteria:\n\n          -  No scar, fibrosis, or atrophy involving the center of the fovea\n\n          -  No retina pigment epithelium (RPE) rip/tear involving the central fovea\n\n          -  Participation in another simultaneous interventional clinical  trial\n\n          -  Prior treatment with anti-VEGF or steroids therapy in the study eye within 28 days of\n             baseline\n\n          -  Prior treatment with photodynamic therapy (PDT)\n\n          -  Intraocular surgery (including cataract surgery) in the study eye within 2 months\n             preceding Baseline\n\n          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for\n             AMD in the study eye\n\n          -  Active intraocular inflammation in the study eye\n\n          -  History of cerebral vascular accident, myocardial infarction, transient ischemic\n             attacks within 3 months of study enrollment.\n\n          -  Unable to undergo fluorescein angiography or fundus photography because of\n             uncontrolled allergies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896284", 
            "org_study_id": "BMF-AFLI-2013-01", 
            "secondary_id": "2013-000848-26"
        }, 
        "intervention": {
            "arm_group_label": "0.5mg AFLIBERCEPT injection", 
            "description": "0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.", 
            "intervention_name": "0.5mg aflibercept", 
            "intervention_type": "Drug", 
            "other_name": "EYLEA"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mitogens", 
                "Endothelial Growth Factors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "contact": {
                "email": "elisabet.molina@tfscro.com", 
                "last_name": "Elisabet Molina, pharmaceutic", 
                "phone": "+34 93 185 02 36"
            }, 
            "contact_backup": {
                "email": "jbadal@institutmacularetina.com", 
                "last_name": "Josep Badal, MD", 
                "phone": "0034-935-950-155"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08022"
                }, 
                "name": "Barcelona Macula Foundation"
            }, 
            "investigator": [
                {
                    "last_name": "Jordi Mones, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Josep Badal, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Hussein Al Muhstaseb, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy.", 
        "overall_contact": {
            "email": "elisabet.molina@tfscro.com", 
            "last_name": "Elisabet Molina, Pharmaceutic", 
            "phone": "+34 93 185 02 36"
        }, 
        "overall_official": [
            {
                "affiliation": "Barcelona Macula Foundation", 
                "last_name": "Jordi Mones, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Cl\u00ednico San Carlos", 
                "last_name": "Carlos Juan Donate, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hosipital Universitario Ramon y Cajal", 
                "last_name": "Marta Su\u00e1rez de Figueroa, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Son Espases", 
                "last_name": "Jose Luis Olea, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario Insular de Canarias", 
                "last_name": "Francisco Cabrera, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital General de Catalunya", 
                "last_name": "Laura Sarasols, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Instituto Cl\u00ednico Quir\u00fargico de Oftalmolog\u00eda de Bilbao", 
                "last_name": "Javier Araiz, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hospital Universitario de Albacete", 
                "last_name": "Jose Maria Ruiz-Moreno, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut Catala de Retina", 
                "last_name": "Ignasi J\u00fcrgens, MD PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "At week 12 an OCT will be performed to evaluate the changes in intra or subretinal fluid and to determine the percentage of patients with no fluid after 3 doses of aflibercept injected on baseline visit, week 4 and week 8.", 
            "measure": "Percentage of patients with no fluid on Optical Coherence Tomography (OCT) after loading dose of aflibercept", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896284"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in best corrected visual acuity (BCVA)after loading dose", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Changes in OCT central foveal thickness after loading dose", 
                "safety_issue": "No", 
                "time_frame": "week 12"
            }, 
            {
                "measure": "Anatomic and Visual Acuity outcomes maintained during (every 8 weeks) treatment.", 
                "safety_issue": "No", 
                "time_frame": "week 40"
            }, 
            {
                "measure": "Determine the time to resolution of any intra/sub retinal fluid on OCT", 
                "safety_issue": "No", 
                "time_frame": "week 4,8,12,24,32,40"
            }, 
            {
                "description": "Describe the safety of aflibercept in study patients by determining ocular and non ocular adverse events classified according to type, frequency and severity during 40 weeks", 
                "measure": "Describe safety of this cohort of patients", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, week 4, 8, 12, 24, 32 and 40"
            }
        ], 
        "source": "Barcelona Macula Foundation", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "TFS Trial Form Support", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Bayer", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Barcelona Macula Foundation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}